Hypertension with Voquezna: A Real but Minimal Clinical Concern
Hypertension does occur with Voquezna (vonoprazan), but the absolute risk increase is small (approximately 1% above placebo in most trials), and this should not prevent its use in most patients, though blood pressure monitoring is warranted. 1
Understanding the Data
You're both correct in different ways. The FDA label does acknowledge hypertension as an adverse event, reporting it in approximately 3% of patients in maintenance trials versus 2% on placebo 1. However, this represents only a 1% absolute increase in risk—a statistically detectable but clinically modest difference.
What the FDA Label Actually Shows
The hypertension rates vary by indication:
- Maintenance of healed erosive esophagitis: 3% with Voquezna vs 2% with placebo 1
- H. pylori treatment trials: 2% with Voquezna combinations 1
- Non-erosive GERD: Not specifically listed as ≥2% adverse event 1
Importantly, no patients discontinued Voquezna due to hypertension in the clinical trials 1. This suggests the blood pressure elevations were generally mild and manageable.
Clinical Implications
Who Needs Monitoring
All patients on Voquezna should have blood pressure monitored, but the intensity varies:
- Patients with pre-existing hypertension: Weekly home BP monitoring for the first month, then at 3 months, then every 6 months 2
- Patients without hypertension history: Check BP at 3 months (when changes first appeared in trials), then every 6 months 2
- Any patient with symptoms: Check immediately if symptoms of hypertension develop 2
The Blood Pressure Pattern
Post-hoc analyses from related S1P receptor modulators (ozanimod, used for ulcerative colitis) showed that blood pressure increases are typically small, occur early, and stabilize over time 2. While this is a different drug class, vonoprazan appears to follow a similar pattern based on available data.
Practical Management Algorithm
Step 1: Pre-treatment Assessment
- Measure baseline blood pressure
- Document any history of hypertension
- Ensure pre-existing hypertension is well-controlled (target <140/90 mmHg per general guidelines) 3
Step 2: Initiate Voquezna
- Start treatment regardless of baseline BP status (unless severely uncontrolled)
- The small risk does not justify withholding effective acid suppression therapy
Step 3: Monitoring Schedule
- Week 4 (if pre-existing hypertension): Home BP check
- Month 3: Office or home BP measurement for all patients
- Every 6 months thereafter: Routine BP monitoring
Step 4: If BP Increases
- Increase <10 mmHg: Continue Voquezna, recheck in 1 month
- Increase 10-20 mmHg or new stage 1 hypertension (130-139/80-89): Intensify lifestyle modifications, consider adding/adjusting antihypertensive if sustained 3
- Increase >20 mmHg or stage 2 hypertension (≥140/90): Initiate or intensify antihypertensive therapy; consider continuing Voquezna if clinically beneficial 3
Context: This is Not Unique to Voquezna
Many commonly used medications cause similar or greater BP increases:
- NSAIDs: Well-established to raise BP and interfere with antihypertensive efficacy 4
- Corticosteroids: Significant BP elevation 5
- Decongestants: Direct vasoconstrictive effects 4
- Some cancer therapies: 80-90% develop hypertension with VEGF inhibitors 5
The 1% absolute increase with Voquezna is modest in comparison.
Bottom Line
The pamphlet is accurate—hypertension does occur slightly more frequently with Voquezna than placebo. However, the absolute risk increase is small, the elevations are typically mild, no patients discontinued due to hypertension in trials, and the condition is easily monitored and managed. This should not be a barrier to using Voquezna when clinically indicated, but it does justify routine blood pressure monitoring, particularly at 3 months and then every 6 months during ongoing therapy 2, 1.